CYP2D6 and Schnyder corneal dystrophy: Targeting specific at-risk populations for acute pain episodes like SCD patients for pre-emptive CYP2D6 genotyping for guided pain intervention is the future that could have enormous benefits by minimizing pain impact on health-related quality of life (QoL), in-hospital periods, reducing cost of care, potentially improving prognosis and enhancing confidence in the use of codeine among pediatric SCD patients.31